Disease burden
Alzheimer’s disease progressively affects memory, thinking and the ability to perform daily activities. Amyloid and tau are important features of the disease, while inflammation, vascular health, metabolism and other processes are also active areas of research.
BioVie’s research approach
BioVie has studied bezisterim in people diagnosed with Alzheimer’s disease, testing the hypothesis that selective modulation of inflammation and improved insulin sensitivity in the brain could influence cognition, function, biomarkers or neurodegeneration.
How to interpret the evidence
BioVie’s Phase 3 Alzheimer’s study experienced protocol deviations and data-integrity limitations that materially affected interpretation. Exploratory analyses can generate hypotheses, but they do not establish efficacy and require confirmation.
Research resources
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.